新诊断中老年2型糖尿病患者的初始治疗策略与血糖控制

目的 了解我国中老年2型糖尿病患者的早期治疗策略、血糖控制及达标情况.方法 对中国糖尿病并发症防治研究中,年龄≥50岁新诊断或病程在1年内的2型糖尿病患者,在20个月内血糖控制、达标情况与早期治疗方案之间的关系进行回顾性分析;771例入选患者根据治疗方案分为未用药、单种口服药组、2种或多种口服药联合治疗组(联合治疗组)、胰岛素治疗组.结果 (1)771例患者调整治疗前均接受过不同方式的治疗,糖化血红蛋白(HbA1c )基线水平7.2%～7.7%;根据HbA1c 基线水平调整治疗方案,未用药组、单种口服药组、联合治疗组、胰岛素治疗组 HbA1c 水平分别为6.1%、7.2%、7.7%、9.2%;(2) 4种治疗方案均能快速有效地控制血糖,在20个月的随访中保持持续达标,随访末时的平均空腹血糖为(6.6±1.5)mmol/L,HbA1c (6.2±1.3)%;以HbA1c ＜7.0%为标准,除胰岛素治疗组达标率在63.2%外,其余各组达标率均在80.0%以上;(3)磺脲类和双胍类药物在单药治疗中均能达到一致的血糖控制及达标率.结论 对中老年2型糖尿病患者,根据其血糖水平制定以磺脲类和双胍类等基本口服药为主的早期多种个体化治疗措施,可以达到有效、长期、安全控制血糖的目的.

Abstract：

Objective To analyze the initial treatment strategies, blood glucose control and reaching standard status of newly diagnosed type 2 diabetes mellitus (T2DM) in the middle-aged and elderly. Methods The 771 patients diagnosed with T2DM newly or within one year, aged 50-70 years, selected from Chinese Diabetes Complication Prevention Study (CDCPS) were enrolled in this study. The correlations of initial treatment strategies with blood glucose control (target value of glycated hemoglobin was less than 7.0%) and reaching standard status were analyzed retrospectively. Based on the same lifestyle intervention, the therapy was further divided into group A (without medication), group B (single oral hypoglycemic agent), group C (combined oral hypoglycemic agents), group D (treatment including insulin). Results Although receiving the different treatments, the 771 patients had a similar mean glycated hemoglobin level, from 7.2% to 7.7%, among the four kinds of intervention before entering the study. The increased intensity and complexity after therapy adjustment along with the increased glycated hemoglobin level was observed at baseline. The corresponding relationships between medication and HbA1c were as follow: without medication-6.1%, single oral hypoglycemic agent-7.2%, combined oral hypoglycemic agents-7.7%, treatment including insulin-9.2%. After 20 months of follow-up, the mean fasting glucose and glycated hemoglobin were 6.6 mmol/L and 6.2%, separately. According to the target glycated hemoglobin level of less than 7.0%, all four-kinds of therapies had high achievement rates, which were all above 80% except that was 63.2% in group D. Sulphonylurea and biguanide as initial single oral hypoglycemic agent therapy had the similar effectiveness on glucose control and target glycated hemoglobin achievement. Conclusions According to the levels of glucose and glycated hemoglobin, multiple individual therapies should be enacted at the beginning of treatment. The strategy mainly based on sulphanylurea and biguanide is proved to be persistently effective in newly-diagnosed middle-aged and elderly diabetic patients in China.

Initial treatment strategies and blood glucose control for newly diagnosed type 2 diabetes mellitus in the middle-aged and elderly

Objective To analyze the initial treatment strategies, blood glucose control and reaching standard status of newly diagnosed type 2 diabetes mellitus (T2DM) in the middle-aged and elderly. Methods The 771 patients diagnosed with T2DM newly or within one year, aged 50-70 years, selected from Chinese Diabetes Complication Prevention Study (CDCPS) were enrolled in this study. The correlations of initial treatment strategies with blood glucose control (target value of glycated hemoglobin was less than 7.0%) and reaching standard status were analyzed retrospectively. Based on the same lifestyle intervention, the therapy was further divided into group A (without medication), group B (single oral hypoglycemic agent), group C (combined oral hypoglycemic agents), group D (treatment including insulin). Results Although receiving the different treatments, the 771 patients had a similar mean glycated hemoglobin level, from 7.2% to 7.7%, among the four kinds of intervention before entering the study. The increased intensity and complexity after therapy adjustment along with the increased glycated hemoglobin level was observed at baseline. The corresponding relationships between medication and HbA1c were as follow: without medication-6.1%, single oral hypoglycemic agent-7.2%, combined oral hypoglycemic agents-7.7%, treatment including insulin-9.2%. After 20 months of follow-up, the mean fasting glucose and glycated hemoglobin were 6.6 mmol/L and 6.2%, separately. According to the target glycated hemoglobin level of less than 7.0%, all four-kinds of therapies had high achievement rates, which were all above 80% except that was 63.2% in group D. Sulphonylurea and biguanide as initial single oral hypoglycemic agent therapy had the similar effectiveness on glucose control and target glycated hemoglobin achievement. Conclusions According to the levels of glucose and glycated hemoglobin, multiple individual therapies should be enacted at the beginning of treatment. The strategy mainly based on sulphanylurea and biguanide is proved to be persistently effective in newly-diagnosed middle-aged and elderly diabetic patients in China.